Skip to main content
    B

    BioRestorative Therapies Inc (BRTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.42
    -0.07 (-4.70%)

    Market Cap: $2.06M

    Last updated: Nov 17, 2026 at 11:00 AM ET

    BioRestorative Therapies Inc (BRTX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect BioRestorative Therapies (BRTX) to earn -$13.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $310000. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$10.40.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 383.9%.

    Fiscal year ending Dec 31, 2026
    -$13.20
    EPS consensus, revenue $310000
    Fiscal year ending Dec 31, 2027
    -$10.40
    EPS consensus, revenue $1.50M
    Next report
    Mar 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$13.20-$13.20 to -$13.201$310000$310000 to $3100001
    Dec 31, 2027-$10.40-$10.40 to -$10.401$1.50M$1.50M to $1.50M1

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.04-$2.55 to -$1.474$395250$98000 to $7087504

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$27.00.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$13.20-$23.40-$23.40-$27.00-$27.00N/A
    Fiscal year ending Dec 31, 2027-$10.40-$19.40-$19.40-$25.40-$25.40N/A

    Frequently Asked Questions About BRTX

    What is the BRTX stock forecast?

    Consensus analyst estimates put BioRestorative Therapies's EPS at -$13.20 for the fiscal year ending Dec 31, 2026, on revenue of $310000.

    What EPS do analysts expect from BRTX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$13.20, with estimates from -$13.20 to -$13.20 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$10.40, with estimates from -$10.40 to -$10.40 from 1 analyst.

    What revenue do analysts expect from BioRestorative Therapies next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $310000, with estimates from $310000 to $310000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.50M, with estimates from $1.50M to $1.50M.

    How many analysts cover BRTX?

    1 analyst estimates EPS for BioRestorative Therapies for the fiscal year ending Dec 31, 2026.